CoCrystal Pharma, Inc. announced that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented on December 1, 2022 at the World Antiviral Congress 2022 underway in San Diego. In November 2022 Cocrystal reported that orally administered CC-42344 showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.555 USD | +2.98% | +1.64% | -9.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.71% | 15.82M | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022